BRCH Portal
 
BRAIN BREAST GI GU GYN
HEAD and NECK LEUKEMIA LUNG LYMPHOMA MELANOMA
MULTIPLE MYELOMA SYMPTOM CONTROL TCC™ TISSUE COLLECTION

 

Boca Raton Community Hospital

Eugene M. and Christine E. Lynn Clinical Research Center (561) 955-4800
The Center for Hematology-Oncology (561) 416-8869 x247
Total Cancer Care™ (561) 955-CARE (2273)

www.floridacancertrials.com/sites/brc

 

 db_trialIDdb_groupIDdb_PrimarySiteCode1db_PrimarySiteCode2Endorsed ByProtocol DescriptionEligibility
5 1 RTOG 0625/ACRIN 6677 Recurrent GBM TEMPORARILY CLOSED BRAIN
RTOG 0625/ACRIN 6677
Recurrent GBM TEMPORARILY CLOSED
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
252 Medical Oncology
14856 AK CHO
A Randomized Phase II Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in recurrent GBM
    db_EligibilityTrialIDdb_trialID 
    75
  • Pt must have rec’d prior temozolomide
    • 85
  • Prior tx with SRS, Gliadel wafer or brachytherapy okay
    • 105
  • Unequivocal radiographic evidence for progression by MRI within 14 days
    • 2895
  • Contact (561) 955-4800
    • 4635
6 1 RTOG 0627 Recurrent GBM TEMPORARILY CLOSED BRAIN
RTOG 0627
Recurrent GBM TEMPORARILY CLOSED
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
461 Radiation Oncology
562 Medical Oncology
Phase II Trial of Dasatinib in patients with recurrent GBM treated with RT + temozolomide
    db_EligibilityTrialIDdb_trialID 
    116
  • MRI or CT brain done within 10 days prior to registration
    • 126
  • Gliadel wafer use excluded
    • 136
  • Scan showing recurrent/progressive GBM
    • 2906
  • Contact (561) 955-4800
    • 4626
8 1 NCCTG 0574 Cerebral Mets BRAIN
NCCTG 0574
Cerebral Mets
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
881 Radiation Oncology
Phase III Randomized Trial of the Role of Whole Brain RT in Addition to Radiosurgery in Patients with 1 to 3 Cerebral Metastases
    db_EligibilityTrialIDdb_trialID 
    168
  • 1-3 presumed brain mets from a histologically confirmed extra-cerebral tumor site (lung, breast, prostate)
    • 178
  • Will receive tx with a gamma knife or a linear accelerator-based SRS system
    • 2918
  • Contact (561) 955-4800
11 2 NSABP B39 WBI vs PBI BREAST
NSABP B39
WBI vs PBI
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
13111 Radiation Oncology
A Randomized Phase III Study of Conventional Whole Breast Irradiation vs. Partial Breast Irradiation for Women with Stage 0, I or II Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    2411
  • DCIS or invasive ca, stage 0, I or II
    • 2511
  • Tumor less than or equal to 3 cm
    • 2611
  • DCIS – must be < 50 y/o, any ER/PR
    • 2711
  • Invasive ca EXCLUDED if > or = 50 y/o AND node neg AND receptor positive
    • 29411
  • Contact (561) 955-4800
12 2 ECOG PACCT-1 Oncotype score to determine tx assignment BREAST
ECOG PACCT-1
Oncotype score to determine tx assignment
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
14122 Medical Oncology
Trial Assigning Individualized Options for Treatment using Oncotype DX Assay Recurrence Score (RS 11-25 are randomized to chemo + hormonal tx OR hormonal tx only ; <11 receive only hormonal tx and > 25 receive chemo and hormonal tx) Register before or after
    db_EligibilityTrialIDdb_trialID 
    2812
  • ER + and/or PR +
    • 2912
  • Her2/neu not over-expressed
    • 3012
  • Axillary node negative & age < 75
    • 3112
  • Tumor 1.1 to 5 cm or 5 mm to 1 cm and unfavorable histological features
    • 3212
  • Candidate for chemo + hormonal therapy
    • 26212
  • Placement of MammoSite excludes pt
    • 29512
  • Contact (561) 955-4800
19 2 NCIC MA17R Hormonal Therapy BREAST
NCIC MA17R
Hormonal Therapy
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
19192 Medical Oncology
Phase III Randomized Double-Blind Randomization to Letrozole or Placebo for women previously diagnosed with breast cancer completing five years of AI either as initial therapy or after tamoxifen
    db_EligibilityTrialIDdb_trialID 
    5619
  • Invasive breast cancer (DCIS excluded)
    • 5719
  • Must have completed 4.5-6 years of an AI
    • 5819
  • May have rec’d tamoxifen prior to AI
    • 5919
  • Last dose of AI and randomization must be < 2 years
    • 29719
  • Contact (561) 955-4800
20 2 NSABP B42 Hormonal Therapy BREAST
NSABP B42
Hormonal Therapy
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
21202 Medical Oncology
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of and AI or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Post-Menopausal Women with Hormone Receptor Positive Invasive Br
    db_EligibilityTrialIDdb_trialID 
    6020
  • Duration of initial hormonal therapy may be 57-63 months, pt must be randomized within 6 months following completion;
    • 6120
  • Therapy must have been an AI or up to 3 years of tamoxifen followed by an AI, no tamoxifen during years 4 and 5
    • 6220
  • Can pre-register pt to receive letrozole at no cost to complete the 5 years of tx if:
    • 6320
  • A) 2-4.5 years of AI; or B) 2-3 years tamoxifen; or C) 2-4.5 years combination of tamoxifen (≤ 3 years) followed by an AI
    • 30320
  • Contact (561) 955-4800
24 2 SWOG 0226 Metastatic-hormonal therapy BREAST
SWOG 0226
Metastatic-hormonal therapy
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
23242 Medical Oncology
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    8124
  • Dx of metastatic ca or multiple sites of new disease (multiple sites of new osseous disease)
    • 8224
  • ER and/or PR positive
    • 8324
  • No prior chemo/hormones or immunotherapy for recurrence or mets
    • 30424
  • Contact (561) 955-4800
80 2 ECOG 5103Chemotherapy, 1st line BREAST
ECOG 5103
Chemotherapy, 1st line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
106802 Medical Oncology
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Pts with lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    25280
  • Patients must meet at least one of the following: A) at least one positive axillary lymph node; B) ER neg tumor ≥1cm; C) ER + ≥ 5 cm; C) ER + ≥1cm but < 5 with a RS of ≥ 11 (ok if enrolled in TAILOR
    • 30080
  • Contact (561) 955-4800
111 2 SenorxContura™ (MLB) BREAST
Senorx
Contura™ (MLB)
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1401111 Radiation Oncology
A Multi-Site Prospective, Non Randomized Study Utilizing the Contura™ Multi-Lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use
    db_EligibilityTrialIDdb_trialID 
    424111
  • Age 50 or older with life expectancy greater than 10 years
    • 425111
  • DCIS and/or invasive, size ≤ 3 cm
    • 426111
  • ER positive, unilateral disease
    • 427111
  • If invasive ca, either SNB alone if neg; or minimum 6 axillary nodes removed and all negative
    • 428111
  • Excluded if prior breast cancer
    • 429111
  • Contact (561) 955-4800
86 2 NCCTG 063D ALTTO Chemotherapy-1st line BREAST
NCCTG 063D ALTTO
Chemotherapy-1st line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
108862 Medical Oncology
A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    27186
  • Pt will receive targeted therapy after all chemo or concurrently with paclitaxel
    • 27286
  • HER2 gene amplification required
    • 27386
  • Node + or node negative with tumor > or = 1 cm
    • 30286
  • Contact (561) 955-4800
129 2 U-Systems somoInSIGHT   BREAST
U-Systems somoInSIGHT

db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1571293 Radiology/Women’s Center
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts. (somo•InSIGHT)
    db_EligibilityTrialIDdb_trialID 
    514129
  • Female age 25 or older
    • 515129
  • Asymptomatic
    • 516129
  • Prior screening mammograms, if available, exhibit history of breast density
    • 517129
  • Not currently pregnant or breastfeeding, or planning for these within next 18mos
    • 518129
  • No breast surgeries or interventional procedures in the past 12 months
    • 519129
  • No history of cancer diagnosis and/or treatment in the past 12 months
    • 520129
  • > 50% preliminary parenchymal density on preliminary assessment by technologistFemales aged 25 or older
130 2 High Risk PEM/MRI  BREAST
High Risk PEM/MRI

db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1581303 Radiology/Women’s Center
Positron Emission Mammography (PEM) Compared to Magnetic Resonance Imaging (MRI) of the Breast as Screening Tool for Women with High Risk for Developing Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    521130
  • Female age 25 or older
    • 522130
  • Assessed to have >25% lifetime risk of breast cancer on basis of one of the following: BRCA positive, family history consistent with Hereditary Breast and Ovarian Cancer with a negative BRCA test result in either an affected family member or if none available, negative test result in subject, LCIS history, GAIL score >25% lifetime risk, or history of Hodgkin's disease treated with mantle radiatio
    • 523130
  • Up-to-date mammography w/o suspicious findings or with negative work up of suspicious finding
    • 524130
  • Current clinical breast exam
76 3 NCCTG 0147 Colon-1st line GI
NCCTG 0147
Colon-1st line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
112762 Medical Oncology
Randomized Phase III Trial of FOLFOX +/- cetuximab after curative resection for patients with Stage III Colon Cancer
    db_EligibilityTrialIDdb_trialID 
    24576
  • Stage III disease, resected
    • 24676
  • Radomization < 56 days post surgery
    • 31176
  • Contact (561) 955-4800
112 3 NSABP 0822Rectal, 1st line GI
NSABP 0822
Rectal, 1st line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1411121 Radiation Oncology
1421122 Medical Oncology
A Phase II Evaluation of Pre-op Chemo-RT Utilizing IMRT in Combination with Capecitabine and Oxaliplatin for Patients with Locally Advanced Rectal Cancer
    db_EligibilityTrialIDdb_trialID 
    430112
  • Dx of rectal ca and colonoscopy within 56 days
    • 431112
  • Transrectal US for T stage, unless other exam demonstrates T4
    • 432112
  • Contact (561) 955-4800
65 3 CALGB 80405Metastatic colorectal GI
CALGB 80405
Metastatic colorectal
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
113652 Medical Oncology
A Phase III Trial of FOLFOX or FOLFIRI with bevacizumab or cetuximab or both for Pts with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
    db_EligibilityTrialIDdb_trialID 
    20465
  • Locally advanced or metastatic colorectal cancer
    • 20565
  • No prior treatment for advanced or metastatic colorectal cancer
    • 20665
  • FOLFOX or FOLFIRI may be chosen by physician
    • 31065
  • Contact (561) 955-4800
25 3 Esophagus/GastricCALGB 80101 GI
Esophagus/Gastric
CALGB 80101
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
110252 Medical Oncology
111251 Radiation Oncology
A Phase III Trial of Adjuvant Chemoradiation after Resection of Gastric and Gastroesophageal Adenocarcinoma
    db_EligibilityTrialIDdb_trialID 
    8425
  • IB, II, IIIA, IIIB or IV with M0
    • 8525
  • No prior chemo or RT
    • 30625
  • Contact (561) 955-4800
29 3 ECOG 5202 Colon-Molecular Markers GI
ECOG 5202
Colon-Molecular Markers
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
25292 Medical Oncology
Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin +/- Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers High-risk patients randomized to tx arms, low-risk pts randomized to observation
    db_EligibilityTrialIDdb_trialID 
    8629
  • Tumor must be ≥ 12 cm from anal verge by endoscopy or surgical exam
    • 8729
  • Tumor specimen must be avialale for eval of microsatellite instability and loss of heterozygosity at 18q, to determine high risk versus low risk tx assignment
    • 8829
  • Stage II = T3 or T4, N0, M0
    • 8929
  • Must have ≥ 8 lymph nodes evaluated
    • 9029
  • Must have ≥ 8 lymph nodes evaluated
    • 30729
  • Contact (561) 955-4800
31 3 Amgen, Spiritt Colorectal, Metastatic, 2nd Line GI
Amgen, Spiritt
Colorectal, Metastatic, 2nd Line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
80315 SG CHO
Randomized, Phase 2 study of FOLFIRI with Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer after FOLFOX
    db_EligibilityTrialIDdb_trialID 
    9131
  • ECOG 0-1
    • 9231
  • Measurable disease
    • 9331
  • No use of CYP3A4 inducers, inhibitors, and substrates
    • 33031
  • Contact (561) 955-6613
34 3 NSABP R04 Rectal GI
NSABP R04
Rectal
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
36341 Radiation Oncology
37342 Medical Oncology
Comparing Preop RT and Capecitabine +/- oxaliplatin with Preop RT and Continuos IV Infusion of 5-FU +/- oxaliplatin in the Tx of Patients with Operable
    db_EligibilityTrialIDdb_trialID 
    20734
  • MUST have transluminal ultrasound for staging
    • 20834
  • Diagnosis of invasive rectal cancer by surgical or endoscopic biopsy
    • 20934
  • Time between diagnosis and treatment < 42 days
    • 30934
  • Contact (561) 955-4800
36 4 Renal cell ECOG 2805 GU
Renal cell
ECOG 2805
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
53362 Medical Oncology
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Pts with Resected Renal Cell Ca
    db_EligibilityTrialIDdb_trialID 
    10036
  • Primary-intact renal cell ca, eligible for nephrectomy with curative intent
    • 10136
  • Randomize 3-10 weeks after surgery
    • 31236
  • Contact (561) 955-4800
75 4 ECOG 5805 Prostate GU
ECOG 5805
Prostate
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
117752 Medical Oncology
Phase II Trial of E7389 (Halichondrin B Analog) in Patients with Metastatic Hormone Refractory Prostate Cancer
    db_EligibilityTrialIDdb_trialID 
    24275
  • 1st line, 2nd line or 3rd line
    • 24375
  • Progressive mets (new/enlarging lesions) or stable mets and rising PSA (4 weeks)
    • 24475
  • Must have had prior tx with bilateral orchiectomy or other primary hormonal therapy with evidence of tx failure
    • 31475
  • Contact (561) 955-4800
131 4 Novartis CRAD001L2202Met renal cell 1st line/2nd line GU
Novartis CRAD001L2202
Met renal cell 1st line/2nd line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1591316 AK CHO
Open-label, multicenter phase II study to compare the efficacy and safety of RAD001as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.
    db_EligibilityTrialIDdb_trialID 
    525131
  • Clear cell(or component) or non-clear cell
    • 526131
  • W/or W/O nephrectomy (partial or total)
    • 527131
  • KPS≥70
    • 528131
  • At least 1 measureable lesion
    • 529131
  • No prior systemic tx for metastatic RCC
    • 530131
  • Contact 561-955-6613
42 5 Dana Farber Cancer Inst PARADIGM Locally advanced HEAD and NECK
Dana Farber Cancer Inst PARADIGM
Locally advanced
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
42422 Medical Oncology
43421 Radiation Oncology
A Randomized Phase III Trial Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatin-Based Chemoradiotherapy with Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced Squamous Cell ca of the Head and Neck
    db_EligibilityTrialIDdb_trialID 
    12442
  • Squamous cell ca of head and neck
    • 12542
  • Primary sites: oral cavity, oropharynx, hypopharynx or larynx
    • 12642
  • Stage III or IV without distant mets
    • 12742
  • No prior chemo or RT ever for any dx
    • 12842
  • No prior surgery for SCCHN
    • 31642
  • Contact (561) 955-4800
127 6 Celgene002 ContinuumCLL Maintenance after 2nd line LEUKEMIA
Celgene002 Continuum
CLL Maintenance after 2nd line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1551278 HA CHO
Randomized, double-blind, placebo-controlled, parallel-group study of lenalidomide as maint. therapy in B-cell CLL following second line therapy
    db_EligibilityTrialIDdb_trialID 
    501127
  • 1st or 2nd regimen must contain purine analog
    • 502127
  • Minimal response of partial response after 2nd line
    • 503127
  • Last 2nd line theray>8 weeks and <16 weeks prior to randomization
    • 505127
  • ECOG ≤2
    • 506127
  • Contact 561-955-6613
123 6 CLL Phase III2nd line GSK913 LEUKEMIA
CLL Phase III
2nd line GSK913
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1521238 HA CHO
Open label, randomized Ofatumumab+Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide alone in relapsed CLL
    db_EligibilityTrialIDdb_trialID 
    485123
  • +CD5, CD19, CD20, CD23, CD79b and surface Ig
    • 486123
  • Active disease
    • 487123
  • At least 1 prior CLL therapy; must have had CR or PR
    • 488123
  • ECOG 0-2
    • 489123
  • No prior stem cell transplant
    • 490123
  • Contact (561) 955-6613
87 7 PrECOG 0501 1st line for IIIB, IV or recurrent NSCLC LUNG
PrECOG 0501
1st line for IIIB, IV or recurrent NSCLC
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
126872 Medical Oncology
A Randomized Phase II Study Evaluating Vandetanib in Combination with Docetaxel and Carboplatin +/- Placebo or Maintenance Therapy with Vandetanib in Patients with IIIB, IV or Recurrent NSCLC
    db_EligibilityTrialIDdb_trialID 
    26687
  • NSCLC stage IIIBor stage IV tht is primary or recurrent
    • 26787
  • Prior adjuvant tx okay if > 1 year
    • 26887
  • Prior malignancy okay if > 3 years
    • 26987
  • Prior RT okay if > 2 weeks
    • 27087
  • Brain mets okay if tx completed > 4 weeks and are stable without steroid therapy
    • 32687
  • Contact (561) 955-4800
82 7 ACRIN 6668/RTOG 0235 Imaging LUNG
ACRIN 6668/RTOG 0235
Imaging
Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma
    db_EligibilityTrialIDdb_trialID 
    25482
  • No prior RT, PS 0-1
    • 25582
  • IIB or III NSCLC tx with chemo + RT (inoperable), OK if on another study
    • 25682
  • Baseline whole body PET, then f/u whole body PET 12-16 weeks after XRT
    • 32582
  • Contact (561) 955-4800
113 7 ACRIN 6678  LUNG
ACRIN 6678

db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1431132 Medical Oncology
FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung Cancer
    db_EligibilityTrialIDdb_trialID 
    433113
  • Newly dx IIIB or IV
    • 434113
  • Recurrent or met NSCLC ok if tx was completed ≥ 3 mo. prior to enrollment with measurable lesion in the chest
    • 435113
  • Plan to start tx w/ a platinum-based, dual-agent regimen at 3 week cycles
    • 436113
  • Excluded if bevacizumab (Avastin) is planned at the initiation of chemo
    • 437113
  • Contact (561) 955-4800
119 7 SURGICALCALGB 140503 LUNG
SURGICAL
CALGB 140503
Phase III Randomized Trial of Lobectomy vs. Sublobar Resection for Small (≤2cm) Peripheral NSCLC
    db_EligibilityTrialIDdb_trialID 
    459119
  • Peripheral lung nodule ≤ 2cm on CT and presumed to be lung cancer
    • 460119
  • Location suitable for lobar or sublobar resection
    • 461119
  • No prior chemo or RT for this disease
122 7 Lilly H3E-JMHDNSCL 1st line LUNG
Lilly H3E-JMHD
NSCL 1st line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1511227 HG CHO
Randomized, open-label, pemetrexed + carboplatin/bevacizumab followed by maint. pemetrexed/bevacizumab vs paclitaxel+ carboplatin/bevacizumab followed by maint. bevacizumab
    db_EligibilityTrialIDdb_trialID 
    479122
  • Stage IIIB w/ pleural effusion or IV disease
    • 480122
  • No prior systemic chemo for NSCL/no adj. tx
    • 481122
  • Measurable or nonmeasurable disease per RECIST
    • 482122
  • No squamous cell histology
    • 483122
  • Contact 561-955-6613
50 7 ECOG 1504 Advanced BAC LUNG
ECOG 1504
Advanced BAC
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
47502 Medical Oncology
Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioloalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features
    db_EligibilityTrialIDdb_trialID 
    15250
  • Stage IIIB with pleural effusion or stage IV
    • 15350
  • May have received up to 1 prior chemo regimen for advanced BAC
    • 15450
  • See protocol for additional eligibility
    • 32150
  • Contact (561) 955-4800
51 7 PrECOG 1505 Chemotherapy, 1st Line LUNG
PrECOG 1505
Chemotherapy, 1st Line
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
48512 Medical Oncology
Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) - IIIA NSCLC
    db_EligibilityTrialIDdb_trialID 
    15551
  • Complete resection of stage IB (> 4 cm) to IIIA (T2-3N0, T1-3N1, T1-3N2)
    • 15651
  • Pt must be 6-12 weeks from thoracotomy
    • 15751
  • Excluded if h/o CVA or TIA
    • 32351
  • Contact (561) 955-4800
125 8 NHL Celgene-001Mantle Cell Relapsed/Refractory Phase II LYMPHOMA
NHL Celgene-001
Mantle Cell Relapsed/Refractory Phase II
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
1531258 HA CHO
Single-arm, open-label, lenalidomide in patients with mantle cell NHL relapsed or progressed after tx with bortezomib or refractory to bortezomib
    db_EligibilityTrialIDdb_trialID 
    491125
  • ECOG0-2
    • 492125
  • Must have had anthracycline/mitoxantrone, cyclophosphamide, rituximab, bortezomib
    • 493125
  • Relapsed/refractory to bortezomib
    • 494125
  • Relapsed after autologous stem cell transplant OK
    • 495125
  • Calc. Cr Clearance ≥30 mL/min
    • 496125
  • Contact (561) 955-6613
88 12 Total Cancer Care™Multiple Disease Sites TCC™ TISSUE COLLECTION
Total Cancer Care™
Multiple Disease Sites
Non-treatment study designed to create a centralized clinical data and tissue repository. Collection of excess tissue, both normal and tumor, removed from patient during surgical procedure or biopsy.
    db_EligibilityTrialIDdb_trialID 
    26388
  • Must be at least 18 years of age
    • 26488
  • Patients with high clinical suspicion or who are diagnosed with localized, recurrent or metastatic cancer
    • 26588
  • Patient will be followed for life
    • 28788
  • Contact (561) 955-2273

   

 

Boca Raton Community Hospital

Eugene M. and Christine E. Lynn Clinical Research Center (561) 955-4800
The Center for Hematology-Oncology (561) 416-8869 x247
Total Cancer Care™ (561) 955-CARE (2273)

www.floridacancertrials.com/sites/brc